Cargando…
Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis
PURPOSE: We designed a phase I/II trial of intraperitoneal (IP) docetaxel plus S-1 to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate its efficacy and safety in gastric cancer patients with peritoneal carcinomatosis (PC). METHODS: Patients with PC confirmed by la...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636429/ https://www.ncbi.nlm.nih.gov/pubmed/23423490 http://dx.doi.org/10.1007/s00280-013-2122-0 |
_version_ | 1782267328871792640 |
---|---|
author | Fushida, S. Kinoshita, J. Kaji, M. Hirono, Y. Goda, F. Yagi, Y. Oyama, K. Sudo, Y. Watanabe, Y. Fujimura, T. |
author_facet | Fushida, S. Kinoshita, J. Kaji, M. Hirono, Y. Goda, F. Yagi, Y. Oyama, K. Sudo, Y. Watanabe, Y. Fujimura, T. |
author_sort | Fushida, S. |
collection | PubMed |
description | PURPOSE: We designed a phase I/II trial of intraperitoneal (IP) docetaxel plus S-1 to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate its efficacy and safety in gastric cancer patients with peritoneal carcinomatosis (PC). METHODS: Patients with PC confirmed by laparoscopy or laparotomy received IP docetaxel on days 1 and 15 and S-1 (80 mg/m(2)) on days 1–14 every 4 weeks. RESULTS: In the phase I part (n = 12), each cohort received escalating doses of docetaxel (35–50 mg/m(2)); the MTD was determined to be 50 mg/m(2) and the RD was determined to be 45 mg/m(2). Dose-limiting toxicities included grade 3 febrile neutropenia and grade 3 diarrhea. In the phase II part (n = 27), the median number of courses was 4 (range 2–11). The 1-year overall survival (OS) rate was 70 % (95 % confidence interval 53–87 %). The overall response rate was 22 % and peritoneal cytology turned negative in 18 of 22 (81 %) patients. The most frequent grade 3/4 toxicities included anorexia (19 %), neutropenia (7 %), and leukopenia (7 %). CONCLUSION: IP docetaxel plus S-1 is active and safety in gastric cancer patients with PC. |
format | Online Article Text |
id | pubmed-3636429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-36364292013-04-29 Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis Fushida, S. Kinoshita, J. Kaji, M. Hirono, Y. Goda, F. Yagi, Y. Oyama, K. Sudo, Y. Watanabe, Y. Fujimura, T. Cancer Chemother Pharmacol Original Article PURPOSE: We designed a phase I/II trial of intraperitoneal (IP) docetaxel plus S-1 to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate its efficacy and safety in gastric cancer patients with peritoneal carcinomatosis (PC). METHODS: Patients with PC confirmed by laparoscopy or laparotomy received IP docetaxel on days 1 and 15 and S-1 (80 mg/m(2)) on days 1–14 every 4 weeks. RESULTS: In the phase I part (n = 12), each cohort received escalating doses of docetaxel (35–50 mg/m(2)); the MTD was determined to be 50 mg/m(2) and the RD was determined to be 45 mg/m(2). Dose-limiting toxicities included grade 3 febrile neutropenia and grade 3 diarrhea. In the phase II part (n = 27), the median number of courses was 4 (range 2–11). The 1-year overall survival (OS) rate was 70 % (95 % confidence interval 53–87 %). The overall response rate was 22 % and peritoneal cytology turned negative in 18 of 22 (81 %) patients. The most frequent grade 3/4 toxicities included anorexia (19 %), neutropenia (7 %), and leukopenia (7 %). CONCLUSION: IP docetaxel plus S-1 is active and safety in gastric cancer patients with PC. Springer-Verlag 2013-02-20 2013 /pmc/articles/PMC3636429/ /pubmed/23423490 http://dx.doi.org/10.1007/s00280-013-2122-0 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Article Fushida, S. Kinoshita, J. Kaji, M. Hirono, Y. Goda, F. Yagi, Y. Oyama, K. Sudo, Y. Watanabe, Y. Fujimura, T. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis |
title | Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis |
title_full | Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis |
title_fullStr | Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis |
title_full_unstemmed | Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis |
title_short | Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis |
title_sort | phase i/ii study of intraperitoneal docetaxel plus s-1 for the gastric cancer patients with peritoneal carcinomatosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636429/ https://www.ncbi.nlm.nih.gov/pubmed/23423490 http://dx.doi.org/10.1007/s00280-013-2122-0 |
work_keys_str_mv | AT fushidas phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis AT kinoshitaj phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis AT kajim phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis AT hironoy phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis AT godaf phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis AT yagiy phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis AT oyamak phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis AT sudoy phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis AT watanabey phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis AT fujimurat phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis AT phaseiiistudyofintraperitonealdocetaxelpluss1forthegastriccancerpatientswithperitonealcarcinomatosis |